The former director of quality assurance at Magellan Diagnostics conspired with executives to conceal a critical flaw in lead tests they knew would result in tens of thousands of false negative tests among lead-exposed children, according to the Department of Justice (DOJ).
Reba Daoust, former Magellan director of quality assurance and regulatory affairs; Amy Winslow, former chief executive officer; and Hossein Maleknia, former chief operating officer, repeatedly misled health clinics and the Food and Drug Administration (FDA) about the accuracy of lead-testing devices made by market leader Magellan, according to a grand jury indictment filed April 4 in U.S. District Court for the District of Massachusetts.
Children are considered lead exposed if blood tests show lead above a certain level. Some of the Magellan tests, including LeadCare Ultra and LeadCare II, included a flaw so they inaccurately showed low or no lead levels among children who potentially had lead levels above acceptable limits.
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.